I think we get GOOD news tomorrow in their call!! Just a guess, but sure does seem fishy, to get that down grade right before they talk to INVESTORS. Wall Street CROOKS can get their cheap shares, and make a killing with IMGN's news tomorrow.
Calling the platform "in question" is a NON STARTER, especial with Novartis announcement this morning. They have to think we are all STUPID, would Novartis continue down a bad path, and ALLOW press on it. No way!!!
Sounds in the neighborhood. Once you get to within a couple hundred million dollars, probably just rounding form there, or could be a tip for the lawyers, they always have their hand in the till. LOL :-)
Thanks for the info!!
Very large market, and many patients with varied medical conditions/status. In particular, for elderly and complicated patients, as my father was, C-Plus will offer a needed/welcome option, and relief that would not be available to them otherwise, with devices that require more invasive and strenuous surgical procedures.
CHF is a horrible condition, and knowing Dr Woodcocks perspective on advancing solutions for PATIENTS that can address HORRIFIC, unmet medical needs, I have to believe, this practical, cost effective, and beneficial device, will receive all the attention it deserves. While Janet does not give a hoot about shareholders, she does kick but to get PATIENTS what they need.
Good comments & visibility, if interested in complete article, Google title, "Sunshine Heart's new device is heartening news"
“All of that makes it intriguing and interesting to the investment clientele,” Gunderson said. “Not only is it a bigger market, but the technology seems to have grabbed the attention of big-name physicians.”
"“The niche that I see for C-Pulse is for patients who cannot climb a flight of stairs, who get tired walking half a block or so, patients for whom an LVAD is not warranted. With this device, there is the potential to reverse the disease or halt the progression.”
"At a time when the value of medical technology is being tied more and more to whether it can reduce overall costs, Gunderson said the impact of reducing hospitalizations or even healing the heart could be significant on the firm’s fortunes."
Nope, I have ONE alias, and don't continually try to engage others on multiple boards with inane argument.
Virtually everything you wrote, and the fact that you CONTINUE to try to waste peoples time on multiple boards, with multiple aliases, and the same SAD/needy schtick. :-(
Yup, believe SSH will too. Also expect same for THOR, they have a distinct patient population from SSH that really needs what they make. Potential overlap really does not present an issue to either company (at this time), based on market size and patient need/specifics. They also have multiple products in play, and VERY sharp/aggressive management. Their management is plotting a strong course in this space, I wouldn't ignore them. They may be more friend than foe/concern, when the time is right.
I have money in both, there are distinct, as well as lots of patients for both. Rather than bash THOR, you might find it financially beneficial to own both. :-)
More to EV's than meet the average eye.
Google article title if interested.
You just BUY the competition, classic role up. He with the biggest balance sheet, or friends with the biggest balance sheet, WINS. PZZI has some friends with deep pockets.
Google article title if interested, "Gasp! There's a worldwide wine shortage"
"Morgan Stanley Research show a shortage last year of nearly 300 million cases with the problem only getting worse."